Could American women use mifepristone-misoprostol pills safely with less medical supervision?

被引:31
作者
Harper, C [1 ]
Ellertson, C
Winikoff, B
机构
[1] Univ Calif San Francisco, Ctr Reprod Hlth Res & Policy, San Francisco, CA 94143 USA
[2] Populat Council, Mexico City, DF, Mexico
[3] Populat Council, New York, NY 10021 USA
关键词
abortion; mifepristone; misoprostol; home use; United States;
D O I
10.1016/S0010-7824(01)00300-6
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Medical methods of early abortion differ from surgical methods in that women themselves can potentially ad-minister the regimens. As currently researched and offered, however, the main regimen used for medical abortion, mifepristone-misoprostol, is highly medicalized, involving several clinic visits and extensive physician involvement. We re-examined the role of clinical supervision in each step of the abortion process. using data collected during a large clinical trial of mifepristone-misoprostol abortions in the US, fielded during 1994-1995. The trial was carried out in 17 geographically diverse centers, including private, public, and nongovernmental organization clinics, and enrolled 2121 women, aged 18-45 years, seeking early abortion (:563 days since last menstrual period). Women received 600 mg oral mifepristone, followed 48 h later by 400 mug oral misoprostol. Evidence suggests that most women can handle most steps of the medical abortion process themselves, effectively and safely. The utility of clinic visits to ingest mifepristone and misoprostol is questionable. For many women, even the follow-up visit could perhaps be replaced by telephone follow-up, combined with home pregnancy tests. Alternatives to the present protocol might allow greater control, comfort, and convenience at lower cost. Where clinician involvement might be useful, mid-level health care providers typically possess the skills necessary to offer the method safely, implying that physicians might be necessary only as complications arise. Future research useful for determining the optimal amount of medical involvement to provide mifepristone-misoprostol safely and effectively should include self-screening tests, label comprehension tests, calendars to aid in calculating gestational age, and the development of special pregnancy tests with telephone Follow-up. (C) 2002 Elsevier Science Inc. All iights reserved.
引用
收藏
页码:133 / 142
页数:10
相关论文
共 30 条
  • [1] Termination of pregnancy at 9-13 weeks' amenorrhoea with mifepristone and misoprostol
    Ashok, PW
    Flett, GM
    Templeton, A
    [J]. LANCET, 1998, 352 (9127) : 542 - 543
  • [2] Mifepristone-misoprostol medical abortion: Who will use it and why?
    Blinder, V
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1998, 179 (05) : 1376 - 1376
  • [3] *CDCP, 1997, MMWR-MORBID MORTAL W, V45, P1123
  • [4] *CDCP, 1992, MMWR-MORBID MORTAL W, V41, P591
  • [5] BLOOD-LOSS IN TERMINATION OF EARLY-PREGNANCY BY VACUUM ASPIRATION AND BY COMBINATION OF MIFEPRISTONE AND GEMEPROST
    CHAN, YF
    HO, PC
    MA, HK
    [J]. CONTRACEPTION, 1993, 47 (01) : 85 - 95
  • [6] Coyaji K, 2000, J Am Med Womens Assoc (1972), V55, P191
  • [7] Accuracy of assessment of pregnancy duration by women seeking early abortions
    Ellertson, C
    Elul, B
    Ambardekar, S
    Wood, L
    Carroll, J
    Coyaji, K
    [J]. LANCET, 2000, 355 (9207) : 877 - 881
  • [8] ELLERTSON C, 1997, REPROD HEALTH MATTER, V9, P149
  • [9] Elul B, 2000, J Am Med Womens Assoc (1972), V55, P169
  • [10] Can women in less-developed countries use a simplified medical abortion regimen?
    Elul, B
    Hajri, S
    Nguyen, TNN
    Ellertson, C
    Ben Slama, C
    Pearlman, E
    Winikoff, B
    [J]. LANCET, 2001, 357 (9266) : 1402 - 1405